butylhydroxybutylnitrosamine has been researched along with Local Neoplasm Recurrence in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grubbs, CJ; Juliana, MM; Lubet, RA; Miller, MS; Moeinpour, FL; Mohammed, A; Sei, S; Shoemaker, RH; Suen, CS | 1 |
| Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
| Fujimoto, K; Hirao, Y; Matsumura, Y; Okajima, E; Ozono, S; Tani, Y | 1 |
| Akaza, H | 1 |
| Yang, DA | 1 |
1 review(s) available for butylhydroxybutylnitrosamine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Butylhydroxybutylnitrosamine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytosine; Humans; Interferon Inducers; Mice; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Rats; Urinary Bladder Neoplasms | 1997 |
4 other study(ies) available for butylhydroxybutylnitrosamine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Naproxen; Neoplasm Recurrence, Local; Neoplasms, Experimental; Pulse Therapy, Drug; Rats; Time Factors; Time-to-Treatment; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Butylhydroxybutylnitrosamine; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Female; Humans; Killer Cells, Natural; Macrophages; Mice, Inbred C57BL; Mitomycin; Neoplasm Recurrence, Local; Neoplasms, Experimental; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Microenvironment; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue.
Topics: Adult; Aged; Aged, 80 and over; Animals; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Papillary; Female; Humans; Male; Mice; Mice, Inbred C3H; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pentosyltransferases; Pyrimidine Phosphorylases; Rats; Rats, Inbred F344; Risk Factors; Species Specificity; Thymidine Phosphorylase; Urinary Bladder; Urinary Bladder Neoplasms | 2007 |
[Inhibitory effect of Chinese herb medicine zhuling on urinary bladder cancer. An experimental and clinical study].
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Butylhydroxybutylnitrosamine; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Rats; Rats, Inbred Strains; Urinary Bladder Neoplasms | 1991 |